Biotech entity
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention Ahmed M. Hamdy, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6.4 in the same window.
Last mentioned: Mar 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention Ahmed M. Hamdy, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6.4 in the same window. Each story carries 4 original sources on average, compared with 2.8 for the broader beat in this window. We currently track 1 Biotech story that mention Diantha Duvall, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Diantha Duvall. Shared-story counts are live from our verified record — not editorial picks.
ASH Annual Meeting
Targeted presentation of initial proof-of-concept data for TakeAim CLL study.
Q4 Earnings Report
Reported $19.4M net income and updated clinical guidance for emavusertib.
PIPE Financing
Secured $20.2 million in initial proceeds with milestone-linked upside.
Erivedge Wind-down
Final Erivedge royalties received before the transition to Oberland.
Curis has transitioned to a pure-play oncology developer, leveraging a $27.2 million gain from the sale of Erivedge royalties to fund its emavusertib clinical programs. With a cash runway extended into 2027, the company is prioritizing its registrational study in lymphoma while reporting high MRD conversion rates in its AML triplet therapy.
Diantha Duvall is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
